Findings

What do systematic reviews say?

7 questions · 9 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 2 · 22.2%Moderate 2 · 22.2%High 2 · 22.2%

Low molecular weight heparin vs no thromboprophylaxis

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.48 [0.35, 0.67]
9 studies · 5408 participants
High

Low molecular weight heparin vs active control

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.81 [0.32, 2.04]
2 studies · 781 participants
Moderate
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.43 [0.17, 1.1]
1 study · 439 participants
Moderate

Low molecular weight heparin vs no prophylaxis

Asymptomatic DVT · adults undergoing KA

It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.14 [0.03, 0.61]
2 studies · 369 participants
Very low

Ultra‐low‐molecular‐weight heparin vs placebo

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.32 [0.16, 0.63]
1 study · 3212 participants
High

Low molecular weight heparin vs no prophylaxis

Symptomatic DVT · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in symptomatic DVT: assessed by presence of symptoms and confirmed by a… compared with no prophylaxis (low certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.61 [0.18, 2.03]
4 studies · 1848 participants
Low

Unfractionated heparin vs low molecular weight heparin

DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity

It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
OR 1.23 [0.28, 5.35]
1 study · 75 participants
Very low

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 1.38 [0.73, 2.63]
3 studies · 1566 participants
Low